A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects

Trial Profile

A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs GSK 2881078 (Primary)
  • Indications Cachexia
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Apr 2017 Results assessing safety, pharmacokinetics and pharmacologic effects of GSK2881078, published in the British Journal of Clinical Pharmacology
    • 19 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Nov 2014, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top